Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM TSE:FAP TSE:OLY NYSEARCA:XLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.55-3.8%$7.21$2.46▼$39.95$1.95M0.8866,468 shs73,521 shsFAPabrdn Asia-Pacific Income Fund VCCC$2.94+0.3%C$2.91C$2.67▼C$3.04C$108.38M0.5456,900 shs7,198 shsOLYOlympia Financial GroupC$132.99+1.4%C$122.48C$95.51▼C$133.66C$320.02M0.271,934 shs2,605 shsXLYConsumer Discretionary Select Sector SPDR Fund$230.16+0.5%$219.68$173.10▼$240.28$23.10B1.184.45 million shs3.23 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%+6.00%-71.35%-71.01%-91.25%FAPabrdn Asia-Pacific Income Fund VCC0.00%+0.69%+0.69%-0.34%+6.93%OLYOlympia Financial Group0.00%+5.59%+7.36%+22.62%+23.95%XLYConsumer Discretionary Select Sector SPDR Fund0.00%+2.35%+3.09%+5.47%+25.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.3655 of 5 stars3.50.00.00.02.00.00.0FAPabrdn Asia-Pacific Income Fund VCCN/AN/AN/AN/AN/AN/AN/AN/AOLYOlympia Financial Group2.9285 of 5 stars2.50.02.50.01.73.31.3XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.0010,684.31% UpsideFAPabrdn Asia-Pacific Income Fund VCC 0.00N/AN/AN/AOLYOlympia Financial Group 3.00BuyC$147.9111.22% UpsideXLYConsumer Discretionary Select Sector SPDR Fund 2.67Moderate Buy$230.15-0.01% DownsideCurrent Analyst Ratings BreakdownLatest FAP, OLY, AIM, and XLY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025OLYOlympia Financial GroupFundamental ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuyC$147.91(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K13.34N/AN/A$0.20 per share12.75FAPabrdn Asia-Pacific Income Fund VCCC$14.12M7.68C$0.45 per share6.60C$2.92 per share1.01OLYOlympia Financial GroupC$102.64M3.12C$11.41 per share11.66C$16.72 per share7.95XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.68N/AN/AN/A-12,594.21%-421.73%-147.54%N/AFAPabrdn Asia-Pacific Income Fund VCCC$11.23MC$0.319.62∞N/A79.52%10.17%2.92%N/AOLYOlympia Financial GroupC$24.45MC$10.1613.09∞N/A23.82%64.95%35.88%N/AXLYConsumer Discretionary Select Sector SPDR FundN/AN/A27.10∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AFAPabrdn Asia-Pacific Income Fund VCCC$0.217.14%N/A68.71%N/AOLYOlympia Financial GroupC$7.205.41%N/A70.86%N/AXLYConsumer Discretionary Select Sector SPDR Fund$1.820.79%N/AN/AN/ALatest FAP, OLY, AIM, and XLY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/20/2025OLYOlympia Financial GroupMonthlyC$0.605.76%8/20/20258/29/20258/29/20257/22/2025OLYOlympia Financial GroupMonthlyC$0.605.95%7/22/20257/31/20257/31/20256/19/2025OLYOlympia Financial GroupMonthlyC$0.606.28%6/19/20256/30/20256/30/20255/21/2025OLYOlympia Financial GroupMonthlyC$0.606.99%5/21/20255/30/20255/30/20256/10/2025FAPabrdn Asia-Pacific Income Fund VCCjun 25C$0.026/23/20251/1/2000(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75FAPabrdn Asia-Pacific Income Fund VCC44.382.850.30OLYOlympia Financial Group6.003.321.59XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%FAPabrdn Asia-Pacific Income Fund VCC13.14%OLYOlympia Financial Group1.17%XLYConsumer Discretionary Select Sector SPDR Fund69.93%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%FAPabrdn Asia-Pacific Income Fund VCC0.31%OLYOlympia Financial Group34.63%XLYConsumer Discretionary Select Sector SPDR FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableFAPabrdn Asia-Pacific Income Fund VCCN/A36.86 millionN/ANot OptionableOLYOlympia Financial Group3252.41 millionN/ANot OptionableXLYConsumer Discretionary Select Sector SPDR Fund147,000100.40 millionN/ANot OptionableFAP, OLY, AIM, and XLY HeadlinesRecent News About These CompaniesAre Cyclical ETFs Worth the Boom and Bust?2 hours ago | finance.yahoo.comLululemon, Wendy’s, Peloton Get Some Institutional Love As Hedge Funds Shuffle Consumer Stocks DeckAugust 15 at 2:01 AM | msn.com5 ETFs to Benefit if Fed Cuts Rate in SeptemberAugust 11, 2025 | zacks.comWhat Tariffs Mean for Your Sector ExposureAugust 8, 2025 | msn.comShould You Invest in the Consumer Discretionary Select Sector SPDR ETF (XLY)?August 6, 2025 | zacks.comTrump Tariff Blows Didn’t Stop These 3 Stocks From Defying Last Week’s Consumer SlumpAugust 4, 2025 | msn.comLooking for Exposure to Amazon Stock (AMZN) Post Q2 Dip? Try These Two ETFsAugust 2, 2025 | msn.comStrong Start to Q2 Earnings Season: 4 Sector ETFs to PlayJuly 30, 2025 | zacks.com4 Sector ETFs to Play on Improving Earnings TrendsJuly 28, 2025 | zacks.comEarnings Scoreboard: 12 of 17 consumer cyclical stocks beat estimates last weekJuly 27, 2025 | msn.comConsumer Durables: Overview, What They Are, ExampleJuly 25, 2025 | fool.comETFs to Consider as Consumer Sentiment Improves in JulyJuly 21, 2025 | zacks.comWeekly Economic Snapshot: Consumer Spending Rebounds Despite Rising InflationJuly 21, 2025 | etftrends.comEConsumer Stocks Post Weekly Gains As Retail Sales Rebound, Inflation Picks Up: Here Are The Top 3 WinnersJuly 21, 2025 | msn.comThe Market Rally Is Gaining Momentum—Don’t Get Left Behind (XLY)...July 17, 2025 | marketbeat.com5 Sector ETFs Set to Power Q2 Earnings GrowthJuly 10, 2025 | zacks.comS&P 500 consumer discretionary sector jumps 8.9% in Q2, Royal Caribbean Cruises, Carnival, Lululemon Athletica among top moversJuly 3, 2025 | seekingalpha.comWeekly Economic Snapshot: Record Highs Amid Rising Inflation & Conflicting SentimentJune 30, 2025 | etftrends.comENorwegian Cruise Line Stock: Is NCLH Underperforming the Consumer Discretionary Sector?June 26, 2025 | msn.comConsumer Discretionary Select Sector SPDR ETF declares quarterly distribution of $0.4470June 23, 2025 | msn.comAmcor Stock: Is AMCR Underperforming the Consumer Discretionary Sector?June 23, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Stocks With Monopoly Power—and Minimal CompetitionBy Gabriel Osorio-Mazilli | August 10, 2025How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?By Jordan Chussler | August 14, 2025Alphabet Reclaims $200 Threshold—Bull Run Reignited?By Ryan Hasson | August 12, 2025AI Glasses to Replace Smartphones? Meta Is Taking Aim at AppleBy Leo Miller | August 16, 2025FAP, OLY, AIM, and XLY Company DescriptionsAIM ImmunoTech NYSE:AIM$2.55 -0.10 (-3.77%) As of 02:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.abrdn Asia-Pacific Income Fund VCC TSE:FAPC$2.94 +0.01 (+0.34%) As of 01:34 PM EasternThe investment objective of the Company is to obtain current income and achieve incidental capital appreciation from investment in long-term securities. The Company seeks to obtain these objectives primarily from investment in long-term debt securities. The Company may invest up to 100 percent of its total assets in Asia-Pacific debt securities.Olympia Financial Group TSE:OLYC$132.99 +1.79 (+1.36%) As of 02:17 PM EasternOlympia Financial Group Inc is engaged in providing financial services. The company's operating segments are Private Health Services Plan division which markets, sells and administers health and dental benefits to business owners; Investment Account Services division specializes in registered account administration; The Currency and Global Payments division provides corporations and private clients a personalized service for buying and selling foreign currencies; The Exempt Edge division is focused on Onboarding fees; The Corporate and Shareholder Services division, which acts as a cost centre and the Corporate Division.Consumer Discretionary Select Sector SPDR Fund NYSEARCA:XLY$230.16 +1.12 (+0.49%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Consumer Discretionary Select Sector SPDR Fund seeks to provide investment results that correspond generally to the price and yield performance of the Consumer Discretionary Select Sector Index (the Index). The Index includes companies from the following industries, media; retail (specialty, multiline, Internet and catalog); hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure equipment and products; and diversified consumer services. The Fund's investment advisor is SSgA Funds Management, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Whirlpool A Screamin’ Buy in 2025? Signs Say Yes Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Why Arista's Blowout Q2 Is Good News for Chip-Giant Broadcom Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access